{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:39:01Z","timestamp":1794645541431,"version":"4.9.1"},"reference-count":166,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Endometrial carcinosarcoma (ECS) is a rare and aggressive histological subtype of endometrial cancer that is associated with a dismal prognosis. It is a biphasic metaplastic carcinoma with a monoclonal origin comprising epithelial and mesenchymal components. The ECS originates from the epithelial components of the tumor, which undergoes an epithelial-to-mesenchymal transition. Approximately half of patients are diagnosed at the early stage of the disease, whereas the other half are diagnosed at the advanced stage. More than one-third of women present with metastatic lymph nodes, and approximately 10% will have distant metastases. Therefore, ECS is the deadliest type of endometrial cancer compared to other high-grade endometrial carcinomas. Surgical resection with adjuvant therapy remains the standard of care in most cases. The rarity of this disease hinders conducting prospective clinical trials to establish the optimal treatment regimens and increase overall survival. There are no specific guidelines for managing these rare and aggressive tumors despite the increasing interest in ECS in the gynecologic oncology community. The present review focuses on all new insights into ECS regarding its epidemiology, pathology, prognosis, and treatment. Furthermore, the molecular characteristics and new treatment regimens for primary (early and advanced stages) and recurrent ECS are discussed in detail.<\/jats:p>","DOI":"10.3390\/medicina61071156","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:55:13Z","timestamp":1750920913000},"page":"1156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Carcinosarcoma of the Endometrium\u2014Pathology, Molecular Landscape and Novel Therapeutic Approaches"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5279-3095","authenticated-orcid":false,"given":"Stoyan","family":"Kostov","sequence":"first","affiliation":[{"name":"Research Institute, Medical University Pleven, 5800 Pleven, Bulgaria"},{"name":"Department of Gynecology, St. Anna University Hospital, Medical University of Varna, 9002 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavor","family":"Kornovski","sequence":"additional","affiliation":[{"name":"Department of Gynecology, St. Anna University Hospital, Medical University of Varna, 9002 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesela","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Department of General and Clinical Pathology, Faculty of Medicine, Medical University Sofia, 2 Zdrave Str., 1432 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyan","family":"Dzhenkov","sequence":"additional","affiliation":[{"name":"Department of General and Clinical Pathology, Forensic Medicine and Deontology, Division of General and Clinical Pathology, Faculty of Medicine, Medical University\u2014Varna \u201cProf. Dr. Paraskev Stoyanov\u201d, 9002 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitar","family":"Metodiev","sequence":"additional","affiliation":[{"name":"Clinical Pathology Laboratory, MHAT \u201cNadezda\u201d Women\u2019s Health Hospital, 1373 Sofia, Bulgaria"},{"name":"Neuropathological Laboratory, University Hospital \u201cSaint Ivan Rilski\u201d, 1431 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Wafa","sequence":"additional","affiliation":[{"name":"St. Louise Frauenklinik, 33098 Paderborn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonka","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Department of Gynecology, St. Anna University Hospital, Medical University of Varna, 9002 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-6159","authenticated-orcid":false,"given":"Stanislav","family":"Slavchev","sequence":"additional","affiliation":[{"name":"Department of Gynecology, St. Anna University Hospital, Medical University of Varna, 9002 Varna, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tsoneva","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Specialized Hospital for Active Treatment of Obstetrics and Gynaecology Dr Shterev, 1330 Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7719-382X","authenticated-orcid":false,"given":"Angel","family":"Yordanov","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Medical University Pleven, 5800 Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103369","DOI":"10.1016\/j.critrevonc.2021.103369","article-title":"Uterine carcinosarcoma: An overview","volume":"163","author":"Pezzicoli","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/GRF.0b013e31821ac635","article-title":"Uterine Carcinosarcoma","volume":"54","author":"Mariani","year":"2011","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ijgc-00009577-200211000-00001","article-title":"Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas","volume":"12","author":"Mccluggage","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ygyno.2020.10.043","article-title":"Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity","volume":"160","author":"Matsuzaki","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/ijgc-2022-004073","article-title":"Endometrial carcinosarcoma","volume":"33","author":"Bogani","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0002-9378(40)90894-8","article-title":"Carcinosarcomatodes of the uterus","volume":"39","author":"Dixon","year":"1940","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2015.03.041","article-title":"Uterine carcinosarcoma: A review of the literature","volume":"137","author":"Cantrell","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","first-page":"173","article-title":"In-depth molecular profiling of the biphasic components of uterine carcinosarcomas","volume":"1","author":"McConechy","year":"2015","journal-title":"J. Path: Clin. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated Molecular Characterization of Uterine Carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.humpath.2021.02.006","article-title":"Molecular subtype diagnosis of endometrial carcinoma: Comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier","volume":"111","author":"Huvila","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2003.12.029","article-title":"Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989\u20131999","volume":"93","author":"Brooks","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/IGC.0b013e318244cedc","article-title":"Incidence and Survival Trends of Uncommon Corpus Uteri Malignancies in the Netherlands, 1989\u20132008","volume":"22","author":"Boll","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2021.05.003","article-title":"Uterine carcinosarcomas: From pathology to practice","volume":"162","author":"Toboni","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/AOG.0b013e318176157c","article-title":"Uterine carcinosarcomas and grade 3 endometrioid cancers: Evidence for distinct tumor behavior","volume":"112","author":"Bansal","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial Cancer","volume":"383","author":"Lu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2021.04.029","article-title":"Uterine serous carcinoma","volume":"162","author":"Bogani","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pappa, C., Le Thanh, V., Smyth, S.L., Zouridis, A., Kashif, A., Sadeghi, N., Sattar, A., Damato, S., Abdalla, M., and Lagan\u00e0, A.S. (2023). Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates\u2014A 10-Year Retrospective Cohort Study from a Single Institution. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196373"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/clinpract11040103","article-title":"New Aspects of Sarcomas of Uterine Corpus\u2014A Brief Narrative Review","volume":"11","author":"Kostov","year":"2021","journal-title":"Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e077974","DOI":"10.1136\/bmjopen-2023-077974","article-title":"Epidemiology, site-specific characteristics and survival of carcinosarcoma: A retrospective study based on SEER database","volume":"13","author":"Tang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3802\/jgo.2018.29.e22","article-title":"Trends of uterine carcinosarcoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","article-title":"Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database","volume":"26","author":"Hosh","year":"2016","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4103\/0973-1482.138197","article-title":"Review literature on uterine carcinosarcoma","volume":"10","author":"Singh","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/cncr.11484","article-title":"Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus","volume":"98","author":"Sherman","year":"2003","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ygyno.2014.02.041","article-title":"Black race independently predicts worse survival in uterine carcinosarcoma","volume":"133","author":"Erickson","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/1097-0142(19800401)45:7<1625::AID-CNCR2820450718>3.0.CO;2-A","article-title":"Postirradiation mixed m\u00fcllerian tumors of the uterus: A comparative clinicopathologic study","volume":"45","author":"Nochomovitz","year":"1980","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ygyno.2006.05.039","article-title":"Radiation-associated endometrial cancers are prognostically unfavorable tumors: A clinicopathologic comparison with 527 sporadic endometrial cancers","volume":"103","author":"Pothuri","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_28","first-page":"996","article-title":"Mutational landscape implicates epithelial-mesenchymal transition gene TGF-\u03b22 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma","volume":"12","author":"Shen","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJM200206063462319","article-title":"Uterine Sarcoma Associated with Tamoxifen Use","volume":"346","author":"Wysowski","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_31","first-page":"225","article-title":"Evaluating Clinical Features in Intracavitary Uterine Pathologies among Vietnamese Women Presenting with Peri-and Postmenopausal Bleeding: A Bicentric Observational Descriptive Analysis","volume":"13","author":"Nguyen","year":"2022","journal-title":"J. Midlife Health"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.AOG.0000275262.60526.01","article-title":"Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer","volume":"110","author":"South","year":"2007","journal-title":"Obstet. Gynecol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13053-021-00185-y","article-title":"A novel germline mutation in hMLH1 in three Korean women with endometrial cancer in a family of Lynch syndrome: Case report and literature review","volume":"19","author":"Jung","year":"2021","journal-title":"Hered. Cancer Clin. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2147\/OTT.S353054","article-title":"Hereditary Gynecologic Cancer Syndromes\u2014A Narrative Review","volume":"15","author":"Kostov","year":"2022","journal-title":"Onco Targets Ther."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ueki, A., and Hirasawa, A. (2020). Molecular Features and Clinical Management of Hereditary Gynecological Cancers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249504"},{"key":"ref_36","unstructured":"WHO of Classification of Tumours Editorial Board (1980). Female Genital Tumors, World Health Organization Classification of Tumours."},{"key":"ref_37","first-page":"783","article-title":"Gan to kagaku ryoho","volume":"49","author":"Higuchi","year":"2022","journal-title":"Cancer Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3802\/jgo.2015.26.4.249","article-title":"Uterine carcinosarcoma\/malignant mixed M\u00fcllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy","volume":"26","author":"Wilson","year":"2015","journal-title":"J. Gynecol. Oncol."},{"key":"ref_39","first-page":"42","article-title":"Dysontogenic and mixed tumours of the urogenital region","volume":"61","year":"1935","journal-title":"Surg. Gynecol. Obstet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1749-6632.1959.tb44576.x","article-title":"Uterine sarcomas: Histogensis and taxonomy","volume":"75","author":"Ober","year":"1959","journal-title":"Ann. N. Y Acad. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.suronc.2018.05.017","article-title":"Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element","volume":"27","author":"Matsuo","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.6004\/jnccn.2009.0037","article-title":"Carcinosarcomas (malignant mixed Mullerian tumor) of the uterus: Advances in elucidation of biologic and clinical characteristics","volume":"7","author":"Kernochan","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004347-199901000-00012","article-title":"Collision of endometrioid carcinoma and stromal sarcoma of the uterus: A report of two cases","volume":"18","author":"Lam","year":"1999","journal-title":"Int. J. Gynecol. Pathol. Jan."},{"key":"ref_44","first-page":"1","article-title":"Carcinosarcomas and epithelial to mesenchymal transition (EMT)","volume":"8","author":"Vassileva","year":"2023","journal-title":"Med. Clin. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1083\/jcb.4.5.583","article-title":"The Fine Structure of Blastema Cells and Differentiating Cartilage Cells in Regenerating Limbs of Amblystoma Larvae","volume":"4","author":"Hay","year":"1958","journal-title":"J. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/PGP.0000000000000497","article-title":"Predictive Histologic Factors in Carcinosarcomas of the Uterus: A Multi-institutional Study","volume":"38","author":"Abdulfatah","year":"2019","journal-title":"Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol."},{"key":"ref_47","first-page":"e20230403","article-title":"Epithelial-mesenchymal transition in uterine carcinosarcoma from a dedifferentiated papillary serous carcinoma to a sarcoma: Case report","volume":"19","author":"Barbosa","year":"2023","journal-title":"Braz. J. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","article-title":"Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?","volume":"7","author":"Peinado","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI36183","article-title":"Biomarkers for epithelial\u2013mesenchymal transitions","volume":"119","author":"Zeisberg","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2016.02.002","article-title":"Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments","volume":"109","author":"Krause","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25880","DOI":"10.1073\/pnas.1911310116","article-title":"Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition","volume":"116","author":"Cuevas","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/ijgc-2018-000038","article-title":"Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma","volume":"29","author":"Osakabe","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_53","first-page":"5379","article-title":"Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors","volume":"57","author":"Wada","year":"1997","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Leskela, S., P\u00e9rez-Mies, B., Rosa-Rosa, J.M., Cristobal, E., Biscuola, M., Palacios-Berraquero, M.L., Ong, S., Matias-Guiu Guia, X., and Palacios, J. (2019). Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma. Cancers, 11.","DOI":"10.3390\/cancers11070964"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jcp.55.5.321","article-title":"Malignant biphasic uterine tumours: Carcinosarcomas or metaplastic carcinomas?","volume":"55","author":"McCluggage","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4103\/IJPM.IJPM_701_20","article-title":"Uterine collision tumor of endometrial stromal sarcoma and endometrioid adenocarcinoma: A rare case report and review of literature","volume":"64","author":"Sharma","year":"2021","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1245\/s10434-018-6547-x","article-title":"Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma","volume":"25","author":"Matsuo","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-019-12985-x","article-title":"Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma","volume":"10","author":"Gotoh","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"636088","DOI":"10.3389\/pore.2021.636088","article-title":"HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line","volume":"27","author":"Stockhammer","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.semdp.2010.09.005","article-title":"Pathologic and molecular features of uterine carcinosarcomas","volume":"27","author":"Palacios","year":"2010","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1038\/modpathol.2015.137","article-title":"A practical approach to the diagnosis of mixed epithelial and mesenchymal tumours of the uterus","volume":"29","author":"McCluggage","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1007\/s00432-023-04594-5","article-title":"Is the sarcomatous component (homologous vs heterologous) the prognostic \u201cdriving force\u201d in early-stage uterine carcinosarcomas? A retrospective multicenter study","volume":"149","author":"Rosati","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.gore.2015.08.002","article-title":"Clinically aggressive \u201clow-grade\u201d uterine carcinosarcoma: A case report","volume":"14","author":"Clearman","year":"2015","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0b013e3181161ba3","article-title":"Prognostic features of surgical stage I uterine carcinosarcoma","volume":"31","author":"Ferguson","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2009.06.018","article-title":"Polypoid or non-polypoid? A novel dichotomous approach to uterine carcinosarcoma","volume":"115","author":"Djordjevic","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e38800","DOI":"10.1097\/MD.0000000000038800","article-title":"Unexpected rare uterine carcinosarcoma with neuroendocrine differentiation: Reflections on clinical diagnosis and treatment of a case report","volume":"103","author":"Shi","year":"2024","journal-title":"Medicine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e257228","DOI":"10.1136\/bcr-2023-257228","article-title":"Uterine carcinosarcoma showing immature teratoid-like differentiation","volume":"16","author":"Naito","year":"2023","journal-title":"BMJ Case Rep. CP"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/PAS.0b013e318093e421","article-title":"Uterine tumors with neuroectodermal differentiation: A series of 17 cases and review of the literature","volume":"32","author":"Euscher","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004347-200104000-00012","article-title":"Uterine carcinosarcoma with melanocytic differentiation","volume":"20","author":"Amant","year":"2001","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/PAS.0000000000002368","article-title":"Clinicopathologic and Molecular Characterization of Gynecologic Carcinosarcomas with a Mesonephric-Like Carcinomatous Component","volume":"49","author":"Mendoza","year":"2025","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3802\/jgo.2023.34.e73","article-title":"Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: A systematic review and meta-analysis","volume":"34","author":"Kim","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"470795","DOI":"10.1155\/2011\/470795","article-title":"Uterine carcinosarcomas (malignant mixed m\u00fcllerian tumours): A review with special emphasis on the controversies in management","volume":"2011","author":"Kanthan","year":"2011","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/annonc\/mdw161","article-title":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma","volume":"27","author":"Matsuo","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Yashar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/00000478-199506000-00007","article-title":"Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis","volume":"19","author":"Sreenan","year":"1995","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_77","first-page":"969","article-title":"Uterine Carcinosarcoma Presenting as Metastatic Osteosarcoma in the Lung: A Case Report and Literature Review","volume":"53","author":"Amin","year":"2023","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2559.1994.tb00512.x","article-title":"p53 immunostaining suggests that uterine carcinosarcomas are monoclonal","volume":"24","author":"Mayall","year":"1994","journal-title":"Histopathology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/modpathol.2011.88","article-title":"Molecular markers and clinical behavior of uterine carcinosarcomas: Focus on the epithelial tumor component","volume":"24","author":"Nijman","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373. Erratum in Nature 2013, 500, 242.","DOI":"10.1038\/nature12325"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Electronic address: Clinicalguidelines@esmo.org Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","article-title":"TCGA Classification of Endometrial Cancer: The Place of Carcinosarcoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Borrego, S.N., Lengyel, E., and Kurnit, K.C. (2022). Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment. Cancers, 14.","DOI":"10.3390\/cancers14184465"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Galant, N., Krawczyk, P., Monist, M., Obara, A., Gajek, \u0141., Grenda, A., Nico\u015b, M., Kalinka, E., and Milanowski, J. (2024). Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115893"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PGP.0000000000000585","article-title":"Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer","volume":"39","author":"Yen","year":"2020","journal-title":"Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"Rudd","year":"2017","journal-title":"Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/cncr.30743","article-title":"Genetic landscape of clear cell endometrial cancer and the era of precision medicine","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41379-022-01066-y","article-title":"Genomic landscape of endometrial carcinomas of no specific molecular profile","volume":"35","author":"Nguyen","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41379-021-00963-y","article-title":"Prospective molecular classification of endometrial carcinomas: Institutional implementation, practice, and clinical experience","volume":"35","author":"Devereaux","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/his.13976","article-title":"Clear cell endometrial carcinoma and the TCGA classification","volume":"76","author":"Travaglino","year":"2020","journal-title":"Histopathology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100123","DOI":"10.1016\/j.modpat.2023.100123","article-title":"Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The Cancer Genome Atlas-like Prognostic Subgroups","volume":"36","author":"Irshaid","year":"2023","journal-title":"Mod. Pathol"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/cancers4030799","article-title":"Endometrial serous carcinoma: Its molecular characteristics and histology-specific treatment strategies","volume":"4","author":"Nakayama","year":"2012","journal-title":"Cancers"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Cai, Y., Han, Q., and Guo, H. (2023). Identifying clinical features and molecular characteristics of the endometrial clear cell carcinoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1286176"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/PGP.0000000000001010","article-title":"Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics","volume":"43","author":"Huvila","year":"2024","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/ijgc-2019-000920","article-title":"Molecular variations in uterine carcinosarcomas identify therapeutic opportunities","volume":"30","author":"Crane","year":"2020","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/s10038-021-00940-y","article-title":"Genomic alterations in gynecological malignancies: Histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms","volume":"66","author":"Mori","year":"2021","journal-title":"J. Hum. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ijgo.14033","article-title":"Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival","volume":"158","author":"Raffone","year":"2022","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ijc.30537","article-title":"Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas","volume":"140","author":"Jones","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Sa\u011fn\u0131\u00e7, S., Tuncer, S.F., Iltar, E., G\u00fcner, F.C., Tuncer, H.A., Do\u011fan, S., and \u015eim\u015fek, T. (2025). Uterine Carcinosarcoma: Adaptation to New FIGO 2023 Staging System Through Clinical Profile and Oncologic Outcomes. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072299"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO Women\u2019s Cancer Committee FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet."},{"key":"ref_104","first-page":"A52","article-title":"Low accuracy of preoperative sampling for diagnosing uterine carcinosarcoma","volume":"33","author":"Pham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Pandita, P., Wang, X., Jones, D.E., Collins, K., and Hawkins, S.M. (2019). Unique Molecular Features in High-Risk Histology Endometrial Cancers. Cancers, 11.","DOI":"10.3390\/cancers11111665"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Chen, X., Guo, Q., Chen, X., Zheng, W., Kang, Y., and Cao, D. (2024). Clinical and multiparametric MRI features for differentiating uterine carcinosarcoma from endometrioid adenocarcinoma. BMC Med. Imaging, 24.","DOI":"10.1186\/s12880-024-01225-4"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5468\/ogs.22053","article-title":"Endometrial thickness and uterine artery Doppler parameters as soft markers for prediction of endometrial cancer in postmenopausal bleeding women: A cross-sectional study at tertiary referral hospitals from Vietnam","volume":"65","author":"Nguyen","year":"2022","journal-title":"Obstet. Gynecol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2007.08.060","article-title":"Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma","volume":"107","author":"Huang","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1245\/s10434-019-07472-y","article-title":"Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis","volume":"26","author":"Liu","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Smyth, S.L., Ripullone, K., Zouridis, A., Pappa, C., Spain, G., Gkorila, A., McCulloch, A., Tupper, P., Bibi, F., and Sadeghi, N. (2025). Uterine Carcinosarcoma\u2014A Retrospective Cohort Analysis from a Tertiary Centre on Epidemiology, Management Approach, Outcomes and Survival Patterns. Cancers, 17.","DOI":"10.3390\/cancers17040635"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Holub, K., and Biete, A. (2018). New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5131-x"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IGC.0000000000001176","article-title":"Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients with Uterine Carcinosarcoma","volume":"28","author":"Ross","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2022.02.012","article-title":"Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma","volume":"165","author":"Zammarrelli","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jso.24861","article-title":"Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery","volume":"117","author":"Matsuo","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients with Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial","volume":"40","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Dahl, M.J., Lofgren, K.A., Haugen, C., Harmon, G.E., Hughes, S.P., and Dahl, K.D.C. (2024). Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1368592"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","article-title":"Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)","volume":"44","author":"Reed","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40944-019-0362-6","article-title":"Treatment and Outcome of Patients with Uterine Carcinosarcoma in a Comprehensive Cancer Network","volume":"18","author":"Hapsari","year":"2020","journal-title":"Indian J. Gynecol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ajog.2019.11.1260","article-title":"Does chemotherapy or radiation benefit surgical stage I uterine carcinosarcoma patients?","volume":"222","author":"Chow","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Yurttas, C., Ladurner, R., Mihaljevi\u0107, A.L., and Stroh\u00e4ker, J. (2024). Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Sarcomatosis. Cancers, 16.","DOI":"10.3390\/cancers16173034"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Psilopatis, I., Damaskos, C., Garmpis, N., Vrettou, K., Garmpi, A., Sarantis, P., Koustas, E., Antoniou, E.A., Kouraklis, G., and Chionis, A. (2023). The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512353"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.suronc.2019.12.002","article-title":"Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier?","volume":"33","author":"Barrios","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ygyno.2014.09.001","article-title":"Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria","volume":"135","author":"Vargo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2008.06.035","article-title":"A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma","volume":"111","author":"Makker","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/radiation4020014","article-title":"Non-Metastatic Uterine Carcinosarcoma: A Tailored Approach or One Size Fits All?","volume":"4","author":"Maione","year":"2024","journal-title":"Radiation"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ygyno.2017.01.010","article-title":"Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/ijgc-2020-001315","article-title":"Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma","volume":"30","author":"McEachron","year":"2020","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7607","DOI":"10.3390\/curroncol29100601","article-title":"Management and Prognosis of Patients with Recurrent or Persistent\/Progressive Uterine Carcinosarcoma","volume":"29","author":"Tung","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Bellone, S., McNamara, B., Mutlu, L., Demirkiran, C., Hartwich, T.M.P., Harold, J., Yang-Hartwich, Y., Siegel, E.R., and Santin, A.D. (2023). Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108873"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"101426","DOI":"10.1016\/j.gore.2024.101426","article-title":"Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification","volume":"54","author":"Soiffer","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100877","DOI":"10.1016\/j.gore.2021.100877","article-title":"Progestin and aromatase inhibitor therapy in recurrent, estrogen\/progestin receptor positive uterine carcinosarcoma: A case report","volume":"38","author":"Liang","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ygyno.2021.09.010","article-title":"Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor\/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)","volume":"163","author":"Edmondson","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13256-017-1262-y","article-title":"Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: A case report","volume":"11","author":"Jurado","year":"2017","journal-title":"J. Med. Case Reports"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref_136","unstructured":"(2025, May 11). Available online: https:\/\/app.biorender.com."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2020.01.020","article-title":"High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer","volume":"157","author":"Engerud","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial","volume":"6","author":"Berton","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: A randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Cibula","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"da Silva, J.L., de Albuquerque, L.Z., Rodrigues, F.R., de Mesquita, G.G., Chaves, C.B.P., Bonamino, M.H., and de Melo, A.C. (2021). The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-09026-6"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib Plus Pembrolizumab in Patients with Advanced Endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.22.01021","article-title":"A Phase Ib\/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111\/KEYNOTE-146): Long-Term Efficacy and Safety Update","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"174","DOI":"10.22514\/ejgo.2024.106","article-title":"Combining lenvatinib and pembrolizumab for the managementofendometrialcarcinosarcoma: Aretrospectivecase series","volume":"45","author":"Chen","year":"2024","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.gore.2024.101479","article-title":"The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma","volume":"55","author":"Ozawa","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"100676","DOI":"10.1016\/j.modpat.2024.100676","article-title":"POLE-mutated uterine carcinosarcomas: A clinicopathologic and molecular study of 11 cases","volume":"38","author":"Hammer","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"100840","DOI":"10.1016\/j.gore.2021.100840","article-title":"Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma","volume":"37","author":"Hunt","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"101322","DOI":"10.1016\/j.gore.2024.101322","article-title":"Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report","volume":"51","author":"Laurent","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2022.05.005","article-title":"Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor","volume":"166","author":"Manara","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: Tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.11.021","article-title":"Molecular landscape of ERBB2\/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions","volume":"180","author":"Nasioudis","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"152150","DOI":"10.1016\/j.anndiagpath.2023.152150","article-title":"Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection","volume":"65","author":"Yoshida","year":"2023","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_160","first-page":"A45","article-title":"Adding trastuzumab to carboplatin and paclitaxel improves overall survival in advanced-stage HER2\/NEU overexpressing uterine serous carcinoma or carcinosarcoma","volume":"34","author":"Lu","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.ygyno.2024.07.294","article-title":"TROP2 as a novel target in uterine carcinosarcoma organoid models","volume":"190","author":"Moufarrij","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1200\/JCO.2023.41.16_suppl.5599","article-title":"Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2","volume":"41","author":"Santin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IGC.0b013e318228f6da","article-title":"Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: Implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody","volume":"21","author":"Bignotti","year":"2011","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2024.04.010","article-title":"Preclinical in vitro and in vivo activity of the RAF\/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas","volume":"187","author":"Demirkiran","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Pillai, M.S.G., Shaw, P., Bhowmik, A.D., Bhattacharya, R., Rao, G., and Dwivedi, S.K.D. (2024). Uterine carcinosarcoma: Unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol., 38.","DOI":"10.1096\/fj.202401991R"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:59:09Z","timestamp":1760032749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/7\/1156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":166,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["medicina61071156"],"URL":"https:\/\/doi.org\/10.3390\/medicina61071156","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]}}}